Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Items Tagged ‘infliximab’

May 6th, 2016

FDA Approves of Biosimilar to Infliximab

By Kanaaz Pereira kanaazpe

The FDA recently approved of a biosimilar (CT-P13) to infliximab, which is used for treating IBD patients, as well as patients suffering from rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The new drug would be the first biosimilar monoclonal antibody approved in the United States. Dr. Edward Loftus, M.D., explains how biosimilars work, and discusses […]

View full entry

Tags: biosimilar, CT-P13, Edward Loftus, FDA, IBD, infliximab, rheumatoid arthritis


May 29th, 2015

Infliximab Quantitation with Reflex to Antibodies to Infliximab

By Margaret Shepard, Communications Specialist Margaret_Marie

From Mayo Medical Laboratories The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab. Maria Willrich, Ph.D. gives a video overview of […]

View full entry

Tags: IBD, infliximab, Mayo Medical Labs


April 30th, 2015

Infliximab for Patients with Severe Ulcerative Colitis

By Margaret Shepard, Communications Specialist Margaret_Marie

Jeanne Tung, M.D., discusses infliximab for patients with severe ulcerative colitis. Specifically, Dr. Tung focuses on a recent study published in Clinical Gastroenterology and Hepatology that studied using an accelerated schedule compared to the usual dosing schedule of 6 weeks. Infliximab, otherwise known as Remicade, was approved for Crohn’s disease in 1997. Clinical trials demonstrated it […]

View full entry

Tags: Clinical Gastroenterology and Hepatology, IBD, infliximab, Jeanne Tung, Remicade, ulcerative colitis


May 23rd, 2014

Infliximab Therapy for Pediatric IBD Patients

By Margaret Shepard, Communications Specialist Margaret_Marie

Jeanne Tung, M. D., discusses a recent article published in Inflammatory Bowel Diseases about long-term infliximab, also known as Remicade, use for pediatric inflammatory bowel disease (IBD). Remicade was approved for Crohn’s disease in 1997 and ulcerative colitis is 2005. This study is important because many parents want to know how long their child will […]

View full entry

Tags: Cedars-Sinai Medical Center, IBD, Inflammatory Bowel Disease Journal, infliximab, Jeanne Tung, pediatric Crohn's disease, pediatrics, ulcerative colitis


Contact Us · Privacy Policy